Table 1.

Study Characteristics of Included Studies

Author Name	Country	Design	Participants Condition at Baseline	Gender Male/ Female	Mean Age (Years)	Number Randomized in Tezepelumab Group				Number Randomized in Placebo Group	Treatment Duration (Weeks)
						70 mg	210 mg	280 mg	Total
Corren J et al, 2021 (a)15	Multi	Phase II Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	NR	≥12	138	137	137	412	138	52
Corren J et al, 2021(b)13	Multi	Phase IIb Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	177/337	51.8	-	128	-	385	130	52
Emson C et al, 202117	Multi	Phase IIb Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	93/177	52	-	135	-	135	135	52
Menzies-Gow A et al, 202123	Multi	Phase III Randomized, Double-blind, Placebo-controlled	12 to 80 years of age with physician -diagnosed asthma	387/672	49.5	-	528	-	528	531	52
NCT0340607822	Multi	Phase III Randomized, Double-blind, Placebo-controlled	Patients must have been receiving OCS for at least six months prior screening	56/94	53.4	-	65	-	65	64	52
Diver S et al, 202116	Multi	Phase II Randomized, Double-blind, Placebo-controlled	12 to 80 years of age with physician -diagnosed asthma	51/65	50.4	-	59	-	59	57	52

Notes: NR, not reported; mg, milligram.